| Imran Saeed Khan, | |
|
550 16th St, 4th Floor, 4551, Box 0110, San Francisco, CA 94143-2549 | |
| (415) 476-6245 | |
| Not Available |
| Full Name | Imran Saeed Khan |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 550 16th St, San Francisco, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013361427 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 156254 (California) | Primary |
| Entity Name | Ucsf Pediatrics Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376614016 PECOS PAC ID: 6204749112 Enrollment ID: O20031106000823 |
News Archive
More than a quarter of patients with cardiovascular disease and a history of smoking also have air flow limitation compatible with chronic obstructive pulmonary disease, Japanese study data show.
REACH3, the market leader in CRM solutions for healthcare, is pleased to announce its inclusion as the newest member of MGMA's prestigious AdminiServe program. REACH3 has developed a new product exclusively for MGMA members called MyPracticeBuilder. The product will allow MGMA members access to sophisticated predictive consumer scoring and marketing applications.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
Beauty injectable fillers such as Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to restore years of lost facial volume in moments. But for the more sensitive aesthetic patient, the possibility of experiencing injection discomfort or bruising inhibits them from receiving the dramatic visual improvement that could be theirs.
› Verified 5 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
More than a quarter of patients with cardiovascular disease and a history of smoking also have air flow limitation compatible with chronic obstructive pulmonary disease, Japanese study data show.
REACH3, the market leader in CRM solutions for healthcare, is pleased to announce its inclusion as the newest member of MGMA's prestigious AdminiServe program. REACH3 has developed a new product exclusively for MGMA members called MyPracticeBuilder. The product will allow MGMA members access to sophisticated predictive consumer scoring and marketing applications.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
Beauty injectable fillers such as Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to restore years of lost facial volume in moments. But for the more sensitive aesthetic patient, the possibility of experiencing injection discomfort or bruising inhibits them from receiving the dramatic visual improvement that could be theirs.
› Verified 5 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
More than a quarter of patients with cardiovascular disease and a history of smoking also have air flow limitation compatible with chronic obstructive pulmonary disease, Japanese study data show.
REACH3, the market leader in CRM solutions for healthcare, is pleased to announce its inclusion as the newest member of MGMA's prestigious AdminiServe program. REACH3 has developed a new product exclusively for MGMA members called MyPracticeBuilder. The product will allow MGMA members access to sophisticated predictive consumer scoring and marketing applications.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
Beauty injectable fillers such as Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to restore years of lost facial volume in moments. But for the more sensitive aesthetic patient, the possibility of experiencing injection discomfort or bruising inhibits them from receiving the dramatic visual improvement that could be theirs.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Imran Saeed Khan, 550 16th St, 4th Floor, 4551, Box 0110, San Francisco, CA 94143-2549 Ph: () - | Imran Saeed Khan, 550 16th St, 4th Floor, 4551, Box 0110, San Francisco, CA 94143-2549 Ph: (415) 476-6245 |
News Archive
More than a quarter of patients with cardiovascular disease and a history of smoking also have air flow limitation compatible with chronic obstructive pulmonary disease, Japanese study data show.
REACH3, the market leader in CRM solutions for healthcare, is pleased to announce its inclusion as the newest member of MGMA's prestigious AdminiServe program. REACH3 has developed a new product exclusively for MGMA members called MyPracticeBuilder. The product will allow MGMA members access to sophisticated predictive consumer scoring and marketing applications.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
Beauty injectable fillers such as Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to restore years of lost facial volume in moments. But for the more sensitive aesthetic patient, the possibility of experiencing injection discomfort or bruising inhibits them from receiving the dramatic visual improvement that could be theirs.
› Verified 5 days ago
Dr. Kathryn Rachel Davis, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 505 Parnassus Ave # 0110, University Of California San Francisco, M691, San Francisco, CA 94143 Phone: 415-476-6245 | |
Dr. David Michael Gordon, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 505 Parnassus Ave # M696, Box 0110, San Francisco, CA 94143 Phone: 415-353-1000 | |
Jayme Congdon, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1500 Owens St, San Francisco, CA 94158 Phone: 415-476-1000 | |
Laurie Song, Pediatrics Medicare: Medicare Enrolled Practice Location: 550 16th St, San Francisco, CA 94158 Phone: 415-514-4079 Fax: 415-476-5354 | |
Ms. Tatiana Goldstein, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 525 Spruce Street, Suite 3, San Francisco, CA 94118 Phone: 415-668-8900 Fax: 415-668-1695 | |
John T Tsukahara, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2340 Clay St, 3rd Floor, San Francisco, CA 94115 Phone: 415-600-1111 | |
William Bernard Solomon, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 45 Castro Street, Suite 232, San Francisco, CA 94114 Phone: 415-565-6810 Fax: 415-565-6844 |